CN1301973C - 杂环衍生物及医药品 - Google Patents

杂环衍生物及医药品 Download PDF

Info

Publication number
CN1301973C
CN1301973C CNB028089774A CN02808977A CN1301973C CN 1301973 C CN1301973 C CN 1301973C CN B028089774 A CNB028089774 A CN B028089774A CN 02808977 A CN02808977 A CN 02808977A CN 1301973 C CN1301973 C CN 1301973C
Authority
CN
China
Prior art keywords
butoxy
group
alkyl
sec
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028089774A
Other languages
English (en)
Chinese (zh)
Other versions
CN1516690A (zh
Inventor
浅木哲夫
浜本泰介
桑野敬市
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18978246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1301973(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of CN1516690A publication Critical patent/CN1516690A/zh
Application granted granted Critical
Publication of CN1301973C publication Critical patent/CN1301973C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CNB028089774A 2001-04-26 2002-04-25 杂环衍生物及医药品 Expired - Lifetime CN1301973C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP129765/2001 2001-04-26
JP2001129765 2001-04-26

Publications (2)

Publication Number Publication Date
CN1516690A CN1516690A (zh) 2004-07-28
CN1301973C true CN1301973C (zh) 2007-02-28

Family

ID=18978246

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028089774A Expired - Lifetime CN1301973C (zh) 2001-04-26 2002-04-25 杂环衍生物及医药品

Country Status (19)

Country Link
US (1) US7205302B2 (enExample)
EP (1) EP1400518B1 (enExample)
JP (1) JP4479152B2 (enExample)
KR (1) KR100921760B1 (enExample)
CN (1) CN1301973C (enExample)
BE (1) BE2016C051I2 (enExample)
BR (1) BRPI0209249B8 (enExample)
CA (1) CA2445344C (enExample)
DE (1) DE60217674T2 (enExample)
DK (1) DK1400518T3 (enExample)
ES (1) ES2276931T3 (enExample)
FR (1) FR16C0042I2 (enExample)
LU (1) LU93266I2 (enExample)
MX (1) MXPA03009800A (enExample)
NL (1) NL300836I2 (enExample)
PT (1) PT1400518E (enExample)
RU (1) RU2283835C3 (enExample)
TW (1) TWI316055B (enExample)
WO (1) WO2002088084A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588598A (zh) * 2013-11-20 2014-02-19 苏州大学 一种制备2-烯醛衍生物的方法

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
FR2869224B1 (fr) * 2004-04-22 2006-06-09 Oreal Compose 2-oxy-acetamide, ses utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
WO2005107687A1 (fr) * 2004-04-22 2005-11-17 L'oreal Compose 2-oxy-acetamide ses utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
EP1871762A2 (en) * 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
MX2010008745A (es) * 2008-02-28 2010-08-30 Nippon Shinyaku Co Ltd Inhibidor de fibrosis.
US8895776B2 (en) 2008-03-18 2014-11-25 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
WO2009154246A1 (ja) * 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
DK2292231T3 (en) * 2008-06-23 2015-12-14 Nippon Shinyaku Co Ltd THERAPEUTIC AGENT FOR SPINAL CHANNEL STENOSIS
PL2289518T3 (pl) 2008-06-23 2017-03-31 Nippon Shinyaku Co., Ltd. Środek terapeutyczny na nieswoiste zapalenie jelit
WO2009157397A1 (ja) * 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US8575175B2 (en) * 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
US8809334B2 (en) 2008-08-13 2014-08-19 Actelion Pharmaceuticals Ltd. Therapeutic compositions containing macitentan
PT3275871T (pt) * 2009-06-26 2020-04-21 Nippon Shinyaku Co Ltd Cristais
WO2011024874A1 (ja) * 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
MX2012005500A (es) 2009-11-13 2012-08-03 Toray Industries Agente terapeutico o profilactico para diabetes.
EP2531492B1 (en) * 2010-02-05 2016-04-13 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
KR101491938B1 (ko) * 2010-07-14 2015-02-10 노파르티스 아게 Ｉｐ 수용체 효능제 헤테로시클릭 화합물
UY34572A (es) 2012-01-13 2013-09-02 Novartis Ag Compuestos heterocíclicos agonistas del receptor ip
JP6121339B2 (ja) 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
WO2013122028A1 (ja) 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
WO2014069401A1 (ja) 2012-10-29 2014-05-08 株式会社カルディオ 肺疾患特異的治療剤
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
CN104829465B (zh) * 2015-02-13 2018-04-27 普济生物科技（台州）有限公司 一种4-异丙氨基-1-丁醇的制备方法
CN106279047B (zh) 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (en) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Amorphous selexipag and process for preparation thereof
CN106467496B (zh) * 2015-08-14 2020-12-08 苏州国匡医药科技有限公司 4-[(5,6-二苯基哌嗪-2-基)(异丙基)胺基]-1-丁醇的制备方法
WO2017040872A1 (en) 2015-09-03 2017-03-09 Teva Pharmaceuticals International Gmbh Solid state forms of selexipag
WO2017042828A2 (en) 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
WO2017042731A1 (en) * 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
WO2017060827A1 (en) * 2015-10-07 2017-04-13 Lupin Limited An imrpoved process for the preparation of selexipag or its pharmaceutically acceptable salts
EP4331607B1 (en) * 2015-12-02 2025-04-30 Nippon Shinyaku Co., Ltd. Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
WO2017109772A1 (en) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Amorphous form of selexipag
KR102828481B1 (ko) 2015-12-23 2025-07-01 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 화합물
EP3192502A1 (en) 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
ES2911531T3 (es) * 2016-04-01 2022-05-19 Honour R&D Procedimiento para la preparación de los derivados de difenilpirazina
CN107286104A (zh) * 2016-04-12 2017-10-24 常州方楠医药技术有限公司 一种赛乐西帕与药用辅料的固体分散体及其制备方法
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
CA3029960A1 (en) * 2016-07-05 2018-01-11 Maithri Drugs Private Limited Novel process for the preparation of 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof
CR20190063A (es) * 2016-07-12 2019-05-27 Revolution Medicines Inc 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
WO2018015974A1 (en) 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018015975A1 (en) * 2016-07-22 2018-01-25 Sun Pharmaceutical Industries Limited Amorphous solid dispersion of selexipag
WO2018022704A1 (en) 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
WO2018021520A1 (ja) 2016-07-29 2018-02-01 東レ株式会社 グアニジン誘導体及びその医薬用途
CN109563055B (zh) * 2016-07-29 2021-12-24 成都苑东生物制药股份有限公司 氨基吡嗪类化合物或盐、异构体、其制备方法及用途
CN106316967B (zh) * 2016-08-19 2019-02-05 上海艾康睿医药科技有限公司 西里帕格中间体及西里帕格的制备方法
WO2018078383A1 (en) 2016-10-27 2018-05-03 Cipla Limited Pharmaceutical composition comprising amorphous selexipag
CA3046025A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
MA47686A (fr) 2017-03-01 2021-05-12 Arena Pharm Inc Compositions comprenant des agonistes du récepteur pgi2 et procédés de préparation associés
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
CN107365275B (zh) * 2017-06-14 2020-07-03 杭州华东医药集团新药研究院有限公司 高纯度的赛乐西帕
EP3658187A1 (en) 2017-07-27 2020-06-03 Allergan, Inc. Prostacyclin receptor agonists for reduction of body fat
IL317489A (en) * 2017-09-28 2025-02-01 Nippon Shinyaku Co Ltd Crystalline Form I of 2-{4-[N-(6,5-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid, a pharmaceutical preparation, a PGI2 receptor agonist and a therapeutic agent containing the crystal
US10407396B2 (en) * 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
KR20200088382A (ko) 2017-11-16 2020-07-22 니뽄 신야쿠 가부시키가이샤 방출 제어 제제
WO2019154363A1 (zh) * 2018-02-07 2019-08-15 南京明德新药研发有限公司 前列环素受体受体激动剂
BR112020016230A2 (pt) 2018-02-21 2020-12-08 Nippon Shinyaku Co., Ltd. Composição granular, método para produção de composição granular, e método para melhoria da propriedade de dissolução de composição granular
CN108558653A (zh) * 2018-05-14 2018-09-21 湖南华腾制药有限公司 赛乐西帕中间体及赛乐西帕的制备方法
CN108863955B (zh) * 2018-08-03 2021-08-13 成都苑东生物制药股份有限公司 二苯基吡嗪类化合物或其药学上可接受的盐、异构体及其制备方法和用途
CN108774183A (zh) * 2018-08-03 2018-11-09 成都苑东生物制药股份有限公司 一种乙二醇类化合物的制备方法
CN109125325B (zh) * 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
WO2020157730A1 (en) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite
JP2022532076A (ja) 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法
WO2020234361A2 (en) 2019-05-21 2020-11-26 Actelion Pharmaceuticals Ltd Methods for transitioning to selexipag
US20220323437A1 (en) 2019-06-11 2022-10-13 Actelion Pharmaceuticals Ltd Methods for treating pulmonary arterial hypertension
JP2022545195A (ja) * 2019-08-19 2022-10-26 日本新薬株式会社 塩
CN114555088A (zh) 2019-10-23 2022-05-27 埃科特莱茵药品有限公司 包含赛乐西帕的药物组合物
MX2022006403A (es) 2019-11-29 2022-08-25 Actelion Pharmaceuticals Ltd Metodos de tratamiento de hipertension de la arteria pulmonar.
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
US20230113077A1 (en) 2020-01-31 2023-04-13 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
US20230073428A1 (en) 2020-02-03 2023-03-09 Actelion Pharmaceuticals Ltd Methods of treating and assessing pulmonary arterial hypertension with selexipag
WO2022106621A1 (en) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Selexipag for use via intracolonic administration
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
IL307277A (en) 2021-03-31 2023-11-01 Nippon Shinyaku Co Ltd Therapeutic material for gait disorders
JP7010404B1 (ja) 2021-03-31 2022-02-10 日本新薬株式会社 歩行障害治療剤
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
CN113968824B (zh) * 2021-11-29 2024-01-19 郑州大学 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
KR20240149924A (ko) 2022-02-15 2024-10-15 유나이티드 세러퓨틱스 코오포레이션 결정질 프로스타시클린 (ip) 수용체 효능제 및 그의 용도
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
CN117304174A (zh) * 2022-06-20 2023-12-29 四川轻化工大学 一种5,6-二苯基吡嗪-2-氮杂环类化合物及其制备方法和应用
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024131672A1 (zh) * 2022-12-20 2024-06-27 长风药业股份有限公司 二苯基吡嗪类衍生物、其制备方法及应用
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
CN116143704B (zh) * 2023-02-27 2025-05-27 广州楷石生物科技有限公司 司来帕格体内代谢物的一氧化氮供体药物
WO2024194449A1 (en) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising a diphenylpyrazine derivative
WO2025009945A1 (ko) 2023-07-06 2025-01-09 재단법인대구경북과학기술원 셀렉시팍을 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학 조성물
CN117510465A (zh) * 2023-11-03 2024-02-06 四川轻化工大学 一种5,6-二苯基吡嗪-2-哌啶类化合物及其制备方法和应用
CN119033790A (zh) * 2023-12-27 2024-11-29 石家庄四药有限公司 一种药物组合物及其用途
CN118619893B (zh) * 2023-12-27 2025-12-19 石家庄四药有限公司 Pgi2受体激动剂化合物、药物组合物和应用
CN118598820B (zh) * 2024-02-06 2025-07-08 石家庄四药有限公司 一种二苯基三嗪类化合物及其制备方法和应用
WO2025196095A1 (en) 2024-03-20 2025-09-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition for treating pulmonary hypertension
CN118903146B (zh) * 2024-07-22 2025-09-12 石家庄四药有限公司 包括化合物syn045的药物组合物、制剂及其制备方法
CN118750498B (zh) * 2024-07-22 2025-07-08 石家庄四药有限公司 一种包括化合物syn045的药物组合物、制剂及制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513135A (en) * 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
US5219510A (en) * 1990-09-26 1993-06-15 Eastman Kodak Company Method of manufacture of cellulose ester film
JPH05208961A (ja) * 1992-01-31 1993-08-20 Eisai Co Ltd イミダゾール誘導体
US5366982A (en) * 1990-07-24 1994-11-22 Rhone-Poulenc Rorer S.A. Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene B4 antagonist activity, their preparation and use in pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL54728A (en) 1977-05-17 1983-06-15 Diamond Shamrock Corp Substituted 1,2,4-triazines and pharmaceutical compositions containing them
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
JPH0733752A (ja) 1993-07-16 1995-02-03 Sankyo Co Ltd ジフェニルピラジン誘導体及び除草剤
AUPP003297A0 (en) * 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513135A (en) * 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
US5366982A (en) * 1990-07-24 1994-11-22 Rhone-Poulenc Rorer S.A. Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene B4 antagonist activity, their preparation and use in pharmaceutical compositions
US5219510A (en) * 1990-09-26 1993-06-15 Eastman Kodak Company Method of manufacture of cellulose ester film
JPH05208961A (ja) * 1992-01-31 1993-08-20 Eisai Co Ltd イミダゾール誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588598A (zh) * 2013-11-20 2014-02-19 苏州大学 一种制备2-烯醛衍生物的方法
CN103588598B (zh) * 2013-11-20 2015-06-17 苏州大学 一种制备2-烯醛衍生物的方法

Also Published As

Publication number Publication date
JPWO2002088084A1 (ja) 2004-09-09
FR16C0042I2 (fr) 2017-03-17
NL300836I2 (enExample) 2016-11-16
PT1400518E (pt) 2007-03-30
BRPI0209249B1 (pt) 2016-04-26
RU2283835C3 (ru) 2021-02-15
US7205302B2 (en) 2007-04-17
WO2002088084A1 (en) 2002-11-07
EP1400518A4 (en) 2005-04-20
FR16C0042I1 (fr) 2016-12-09
CA2445344C (en) 2011-07-26
RU2283835C2 (ru) 2006-09-20
JP4479152B2 (ja) 2010-06-09
TWI316055B (enExample) 2009-10-21
LU93266I2 (fr) 2016-12-19
DK1400518T3 (da) 2007-03-26
BE2016C051I2 (enExample) 2021-07-19
MXPA03009800A (es) 2004-01-29
KR100921760B1 (ko) 2009-10-15
ES2276931T3 (es) 2007-07-01
US20040102436A1 (en) 2004-05-27
RU2003134190A (ru) 2005-06-10
EP1400518B1 (en) 2007-01-17
CA2445344A1 (en) 2002-11-07
DE60217674T2 (de) 2007-10-11
BRPI0209249B8 (pt) 2021-05-25
KR20040015174A (ko) 2004-02-18
BR0209249A (pt) 2004-06-08
CN1516690A (zh) 2004-07-28
EP1400518A1 (en) 2004-03-24
DE60217674D1 (de) 2007-03-08

Similar Documents

Publication Publication Date Title
CN1301973C (zh) 杂环衍生物及医药品
CN1097051C (zh) N－杂芳基吡啶磺酰胺衍生物及其作为内皮素拮抗剂的用途
CN1293056C (zh) 作为神经激肽－1受体拮抗剂的4－苯基－吡啶衍生物
CN1242995C (zh) 化合物,它们的用途和制备方法
CN1207289C (zh) 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体
CN1179945C (zh) 吲哚衍生物、其制备方法及用途
CN1281604C (zh) 取代吡唑化合物
CN1255401C (zh) 芳基－哌嗪衍生物、及其制备和作为速激肽拮抗剂的应用
CN1149214C (zh) 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
CN1933838A (zh) 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺
CN1653047A (zh) 抗炎症药物单环芳酰吡啶酮
CN1070173C (zh) 用作药物的苯甲酰基胍衍生物
CN1662236A (zh) 组蛋白脱乙酰基转移酶抑制剂
CN1642938A (zh) 新化合物
CN1209125A (zh) 作为速激肽拮抗剂的哌嗪类衍生物
CN1897936A (zh) 环状胍、含有这种化合物的组合物及其使用方法
CN1169792C (zh) 取代的乙烯基吡啶衍生物和含有它们的药物
CN1053658C (zh) 氨基芪唑衍生物和药
CN1119856A (zh) Hiv逆转录酶抑制剂
CN1656086A (zh) 苯并呋喃衍生物
CN1291984C (zh) 2－硫－取代咪唑衍生物及其药学用途
CN1114591C (zh) 环酰胺化合物
CN1147469C (zh) 带有芳香族含氮杂环的新型脲衍生物
CN1571781A (zh) 4－咪唑啉－2－酮化合物
CN1040366A (zh) 丁烯酸或丙烯酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20070228

CX01 Expiry of patent term